Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study

Aims Serial invasive endomyocardial biopsies (EMB) remain the gold standard for acute cellular rejection (ACR) diagnosis. However histological grading has several limitations. We aimed to explore the value of myocardial Gene Expression Profiling (GEP) for diagnosing and identifying predictive biomarkers of ACR. Methods A case-control study nested within a retrospective heart transplant patients cohort included 126 patients with median (IQR) age 50 (41-57) years and 111 (88%) males. Among 1157 EMB performed, 467 were eligible (i.e, corresponding to either ISHLT grade 0 or >= 3A), among which 36 were selected for GEP according to the grading: 0 (C-ISHLT, n = 13); rejection >= 3A (R-ISHLT, n = 13); 0 one month before ACR (BRISHLT, n = 10). Results We found 294 genes differentially expressed between C-ISHLT and R-ISHLT, mainly involved in immune activation, and inflammation. Hierarchical clustering showed a clear segregation of C-ISHLT and R-ISHLT groups and heterogeneity of GEP within R-ISHLT. All EMB presented immune activation, but some R-ISHLT EMB were strongly subject to inflammation, whereas others, closer to C-ISHLT,were characterized by structural modifications with lower inflammation level. We identified 15 probes significantly different between BRISHLT and C-ISHLT, including the gene of the muscular protein TTN. This result suggests that structural alterations precede inflammation in ACR. Linear Discriminant Analysis based on these 15 probes was able to identify the histological status of every 36 samples. Conclusion Myocardial GEP is a helpful method to accurately diagnose ACR, and predicts rejection one month before its histological occurrence. These results should be considered in cardiac allograft recipients' care.